TOI Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

-0.090

-35.71%

-0.093

-55.56%

Estimates Revision

The market is revising Upward the revenue expectations for The Oncology Institute, Inc. (TOI) for FY2025, with the revenue forecasts being adjusted by 5.37% over the past three months. During the same period, the stock price has changed by 9.46%.

Revenue Estimates for FY2025

Revise Upward

+5.37%

In Past 3 Month

EPS Estimates for FY2025

No Change

0.00%

In Past 3 Month

Stock Price

Go Up

+9.46%

In Past 3 Month

3 Analyst Rating

Wall Street analysts forecast TOI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TOI is 7.00 USD with a low forecast of 6.00 USD and a high forecast of 8.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

3 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.000

Low

6.00

Averages

7.00

High

8.00

Current: 0.000

Low

6.00

Averages

7.00

High

8.00

Needham

Buy

initiated

2025-11-25

Reason

Needham

Price Target

2025-11-25

initiated

Buy

Reason

Needham initiated coverage of Oncology Institute with a Buy rating and $5 price target. As value-based care adoption accelerates, Oncology Institute appears well positioned to help curb rising oncology costs, with early relationships typically starting in fee-for-service and expanding into downside risk, the analyst tells investors in a research note. Demand supports a durable 20%+ growth outlook, a shift toward VBC could lift EBITDA margins into the mid-single digits, and shares look undervalued ahead of expected positive EBITDA in Q4 and FY26, the firm says.

Needham

Matthew Shea

initiated

2025-11-25

Reason

Needham

Matthew Shea

Price Target

2025-11-25

initiated

Reason

Needham analyst Matthew Shea initiated coverage of Oncology Institute with a Buy rating and $5 price target. The need for solutions that can mitigate oncology cost trends "could not be more apparent," says the analyst, who views Oncology Institute as "a critical player in addressing this gap." The firm sees demand seeding durable 20%-plus topline growth and sees an opportunity for EBITDA margins to scale towards mid-single digits over the medium term as mix shifts towards value-based care, the analyst tells investors.

Noble Capital

Outperform

initiated

2025-07-23

Reason

Noble Capital

Price Target

2025-07-23

initiated

Outperform

Reason

Noble Capital initiated coverage of Oncology Institute with an Outperform rating and $8 price target. The medical practice management company specializing in community-based oncology practices manages and operates oncology clinics in five states, notes the analyst, who believes that trends in cost containment "will work in TOI's favor." The firm estimates FY26 revenues of $583.4M, the analyst noted.

B. Riley

Buy

initiated

2025-07-16

Reason

B. Riley

Price Target

2025-07-16

initiated

Buy

Reason

B. Riley initiated coverage of Oncology Institute with a Buy rating and $6 price target. The firm says Oncology Institute is one of the largest oncology specialty value-based healthcare service providers. The company's recent debt facility amendment removed a key financial overhang on the shares, the analyst tells investors in a research note.

BTIG

initiated

2025-05-15

Reason

BTIG

Price Target

2025-05-15

initiated

Reason

BTIG initiated coverage of Oncology Institute with a Buy rating and $7 price target. The company specializes in the treatment and management of cancer patients through a blend of both fee-for-service, capitated, and value-based-care contracts, the analyst tells investors in a research note. The firm says that with the aging of America and rising complex care cost trends amongst some health plans, especially in Medicare Advantage, fee-for-service revenue within Oncology Institute will rise through 2025. Demand for capitated and managed care, sub-contracted risk will likely increase as well, contends BTIG.

Valuation Metrics

The current forward P/E ratio for Oncology Institute Inc (TOI.O) is -10.49, compared to its 5-year average forward P/E of -6.36. For a more detailed relative valuation and DCF analysis to assess Oncology Institute Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-6.36

Current PE

-10.49

Overvalued PE

1.53

Undervalued PE

-14.25

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

343.77

Current EV/EBITDA

8828.80

Overvalued EV/EBITDA

2113.22

Undervalued EV/EBITDA

-1425.68

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

0.50

Current PS

0.61

Overvalued PS

1.17

Undervalued PS

-0.17

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

N/A

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds areSelling! The selling amount has increased 47487.34% over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

TOI News & Events

Events Timeline

No data

News

5.0

13:40 PMNewsfilter

The Oncology Institute Appoints New CIO and CPO to Enhance Leadership in Value-Based Cancer Care

2.0

2025-12-18NASDAQ.COM

Biotech Sector Sustains After-Hours Trading Gains

6.0

2025-11-25Benzinga

Needham Begins Coverage of Oncology Institute with Buy Rating and Sets Price Target at $5

People Also Watch

Frequently Asked Questions

What is Oncology Institute Inc (TOI) stock price today?

The current price of TOI is 4.28 USD — it has decreased -0.7 % in the last trading day.

What is Oncology Institute Inc (TOI)'s business?

The Oncology Institute, Inc. is a value-based oncology company. The Company manages community-based oncology practices which serve patients at approximately 86 clinic locations across 16 markets and five states throughout the United States. The Company's segment includes patient services, dispensary, and clinical trials & other. Its managed clinics provide a range of medical oncology services, including physician services, in-house infusion, radiation, and programs like outpatient blood product transfusions, along with 24/7 patient support. The Company, through TOI Clinical Research, LLC (TCR), provides and manages clinical trial services and research for the benefit of cancer patients. The Company also provides management services to over 14 clinic locations owned by independent oncology practices. The Company and its affiliated providers have contractual relationships with payors serving a variety of patients, including Medicare Advantage (MA), Medicaid, and commercial patients.

What is the price predicton of TOI Stock?

What is Oncology Institute Inc (TOI)'s revenue for the last quarter?

Oncology Institute Inc revenue for the last quarter amounts to 136.56M USD, increased 36.70 % YoY.

What is Oncology Institute Inc (TOI)'s earnings per share (EPS) for the last quarter?

Oncology Institute Inc. EPS for the last quarter amounts to -0.14 USD, decreased -22.22 % YoY.

What changes have occurred in the market's expectations for Oncology Institute Inc (TOI)'s fundamentals?

How many employees does Oncology Institute Inc (TOI). have?

Oncology Institute Inc (TOI) has 825 emplpoyees as of January 09 2026.

What is Oncology Institute Inc (TOI) market cap?

Today TOI has the market capitalization of 424.02M USD.